


PRODUCT INFORMATION



SIB 1757

Item No. 35442

CAS Registry No.: 31993-01-8
Formal Name: 6-methyl-2-(2-phenyldiazenyl)-3-pyridinol
MF: C₁₂H₁₁N₃O
FW: 213.2
Purity: ≥95%
UV/Vis.: λ_{max}: 238, 300, 383 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SIB 1757 is supplied as a solid. A stock solution may be made by dissolving the SIB 1757 in the solvent of choice, which should be purged with an inert gas. SIB 1757 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of SIB 1757 in ethanol is approximately 5 mg/ml and approximately 14 mg/ml in DMSO and DMF.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of SIB 1757 can be prepared by directly dissolving the solid in aqueous buffers. The solubility of SIB 1757 in PBS (pH 7.2) is approximately 0.11 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

SIB 1757 is an antagonist of metabotropic glutamate receptor 5a (mGluR5a).¹ It selectively inhibits glutamate-induced calcium release and quisqualate-induced phosphoinositol accumulation in fibroblasts expressing human mGluR5a (IC₅₀s = 0.37 and 3.1 μM, respectively) over mGluR1b-expressing fibroblasts (IC₅₀s = >100 μM for both). SIB 1757 is also selective for mGluR5a over mGluR2, mGluR3, mGluR4a, mGluR6, mGluR7b, mGluR8 (IC₅₀s = >100 μM for all), as well as AMPA, kainate, and NMDA receptors (IC₅₀s = >30 μM for all). It inhibits phosphoinositol accumulation induced by the group I mGluR agonist (S)-3,5-DHPG (Item No. 14411) in isolated neonatal rat hippocampus and striatum (IC₅₀s = 5.2 and 10.1 μM, respectively). Intrathecal administration of SIB 1757 (0.01 μg/animal) increases the paw withdrawal threshold in a rat model of neuropathic pain induced by spinal nerve ligation.²

References

1. Varney, M.A., Cosford, N.D., Jachec, C., *et al.* SIB-1757 and SIB-1893: Selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. *J. Pharmacol. Exp. Ther.* **290**(1), 170-181 (1999).
2. Dogrul, A., Ossipov, M.H., Lai, J., *et al.* Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGluR₅) antagonist, in experimental neuropathic pain in rats. *Neurosci. Lett.* **292**(2), 115-118 (2000).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM